Advertisement
U.S. markets open in 7 hours 47 minutes
Advertisement

Editas Medicine, Inc. (EDIT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Visitors trend2W10W9M
11.05+0.28 (+2.60%)
At close: 04:00PM EST
11.11 +0.06 (+0.54%)
After hours: 07:44PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Intermediate-term KST

Intermediate-term KST

Performance Outlook
Previous Close10.77
Open10.75
Bid0.00 x 900
Ask0.00 x 1000
Day's Range10.54 - 11.25
52 Week Range6.08 - 11.93
Volume1,549,745
Avg. Volume1,710,738
Market Cap902.494M
Beta (5Y Monthly)1.96
PE Ratio (TTM)N/A
EPS (TTM)-2.76
Earnings DateFeb 20, 2024 - Feb 26, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.53
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for EDIT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Editas Medicine, Inc.
    Daily – Vickers Top Buyers & Sellers for 01/05/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    2 years agoArgus Research
View more
  • Simply Wall St.

    Editas Medicine, Inc. (NASDAQ:EDIT) is a favorite amongst institutional investors who own 69%

    Key Insights Institutions' substantial holdings in Editas Medicine implies that they have significant influence over...

  • InvestorPlace

    Hidden Gems for Hefty Returns: 3 Stocks Set to Double Your Wealth Next Year

    On Nov. 25, 2022, I mentioned three stocks to buy that could soar in 2023. At the time, those included Advanced Micro Devices (NASDAQ:AMD), which ran from $73 to $121.53; Apple (NASDAQ:AAPL), which ran from $146 to $191.45; and Nvidia (NASDAQ:NVDA), which ran from $152 to $504. Today, I was asked for a new list of stocks to buy that could double in the new year. So far, I like what I still see with artificial intelligence (AI), cryptocurrencies and gene editing. Advanced Micro Devices (AMD) Sour

  • InvestorPlace

    The 3 Best Gene Editing Stocks on the Frontier of Medicine

    Some of the best gene editing stocks could soon see a massive boost. In just days, the U.S. FDA could approve the first gene-editing treatment of sickle cell disease (SCD) from CRISPR Therapeutics (NASDAQ:CRSP), a move that could set off a firestorm of interest in all things gene editing. All after a U.S. FDA advisory panel gave it the green light just days ago. While CRSP already ran from about $37.50 to $67.89, it could see higher highs as it nears its Dec. 8 PDUFA date with the U.S. FDA. Even